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were eligible to be recruited to the study, but were not randomised. Three of these did not agree to participate in the study and 2 did not complete the pad test. The authors did not present any evidence of whether this patient sample was appropriate to the clinical question.
Study design
The study was a randomised, controlled trial that was carried out in a single centre. The patients were randomised using block randomisation, stratified according to whether the patient had mild or moderate incontinence. The outpatient clerk administered opaque envelopes containing computer-generated random numbers. Neither the patient nor the health professionals in the study were blinded to the treatment group. The patients were assessed at the end of the 12-week trial, then followed up for at least 2 years. The overall loss to follow-up at the end of the 12-week trial was 24.1%, 21.6% in the nurse advisor group versus 26.7% in the comparator group. At the 2-year follow-up, the overall loss was 33.8% of all randomised patients, 36.5% in the nurse advisor group versus 31.0% in the comparator group.
Analysis of effectiveness
The primary analysis of the study appears to have been based on treatment completers only. However, a further analysis, which included those patients who were lost to follow-up, was undertaken. One analysis assumed that all those who were lost to follow-up were cured, while another assumed that treatment failed for all of these patients.
The effectiveness of the two treatments was assessed at the end of the 12-week trial. The outcomes assessed were the change in the level of incontinence, use of incontinence pads and quality of life. Measures for these included a pad test (dry indicates overall cure), the number of voids per day, the number of leaks per week, the number of pads used per day, a 20-point incontinence score, and the long and short forms of two disease-specific quality of life tests.
There appears to have been differences in the baseline characteristics of the two patient groups. Those allocated to the urogynaecology team were older than those in the nurse advisor team. They also had lower scores on some of the quality of life indicators and a small urinary loss on the initial pad test.
Effectiveness results
The overall cure rate (dry pad test) for women was 64% in the nurse advisor group versus 52% in the comparator group. This gave an odds ratio of 1.63 (0.71 -3.75) in favour of the nurse advisor group. However, this result was not statistically significant. At the end of the 12-week trial there were no statistically significant differences between the two groups in any of the other outcome measures. There were also no statistically significant differences between the two groups in the measures of effectiveness used at the 2-year follow-up.
Clinical conclusions
The authors concluded that there was no difference in the effectiveness of conservative treatment delivered by urogynaecologists and specialist nurse advisors.
Measure of benefits used in the economic analysis
No difference in the effectiveness of the two treatment groups was found. In effect, a cost-minimisation analysis was undertaken.
Direct costs
The hospital costs were included. The study examined the staffing costs incurred by the hospital for the two treatment groups. The hourly costs of the nurse advisors, the urogynaecology team and the physiotherapists were reported, but the source of these unit costs was not. The number and duration of visits to nurse advisors and the urogynaecology team were recorded prospectively in the medical notes of the patients included in the trial. The number and duration of physiotherapy appointments were obtained by asking the relevant patients. Discounting was not undertaken since the duration of the trial was 12 weeks. The price year was 1998. The study originally aimed to assess the personal costs
